GHRH and GHRPs as Anti-Aging Therapeutics to Restore Declining Growth Hormone

GHRH and GHRPs offer promising approaches to restore age-related GH decline, addressing the visceral fat accumulation and metabolic changes of GH deficiency in aging.

Thorner, M O et al.·Recent progress in hormone research·1997·Moderate EvidenceReview
RPEP-00434ReviewModerate Evidence1997RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

GHRH and GHRPs can restore GH secretion in aging and disease, addressing the visceral fat accumulation and metabolic changes associated with GH decline.

Key Numbers

How They Did This

Review chapter discussing the pathophysiology of GH decline and the therapeutic potential of GHRH and GHRPs across aging and disease states.

Why This Research Matters

Age-related GH decline affects virtually everyone, contributing to body composition changes and metabolic deterioration. Secretagogue therapy offers a practical, physiological approach to restoring youthful GH levels.

The Bigger Picture

This review positioned GH secretagogues as anti-aging therapeutics, anticipating the current interest in peptide-based approaches to healthy aging.

What This Study Doesn't Tell Us

Review chapter; long-term safety of chronic GH stimulation in aging not fully established. Cancer risk with chronically elevated GH/IGF-1 is debated.

Questions This Raises

  • ?Is long-term GH secretagogue therapy safe for aging populations?
  • ?Which patients benefit most from GHRH vs. GHRP approaches?

Trust & Context

Key Stat:
GH decline drives aging changes Age-related GH decline contributes to visceral fat increase, muscle loss, and metabolic deterioration — all potentially addressable with secretagogues
Evidence Grade:
Moderate evidence from a comprehensive review covering aging, disease, and therapeutic applications of GH secretagogues.
Study Age:
Published in 1997, this review anticipated the current interest in peptide-based anti-aging interventions.
Original Title:
Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging.
Published In:
Recent progress in hormone research, 52, 215-44; discussion 244-6 (1997)
Database ID:
RPEP-00434

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Why does GH decline with age?

Multiple factors: the hypothalamus produces less GHRH, somatostatin inhibition increases, body fat accumulation (which suppresses GH) increases, and IGF-1 feedback becomes more inhibitory. The result is a progressive decline in GH pulsatility.

Are GH secretagogues better than GH injections?

Potentially. Secretagogues preserve the body's natural pulsatile GH release pattern and are self-limiting (the pituitary can only release what it has). GH injections bypass this regulation and can cause more side effects at higher doses.

Read More on RethinkPeptides

Cite This Study

RPEP-00434·https://rethinkpeptides.com/research/RPEP-00434

APA

Thorner, M O; Chapman, I M; Gaylinn, B D; Pezzoli, S S; Hartman, M L. (1997). Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging.. Recent progress in hormone research, 52, 215-44; discussion 244-6.

MLA

Thorner, M O, et al. "Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging.." Recent progress in hormone research, 1997.

RethinkPeptides

RethinkPeptides Research Database. "Growth hormone-releasing hormone and growth hormone-releasin..." RPEP-00434. Retrieved from https://rethinkpeptides.com/research/thorner-1997-growth-hormonereleasing-hormone-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.